Despite global progress against malaria, in 2015 over 200 million people were infected and 438,000 people died from the disease, mostly in sub-Saharan Africa. Furthermore, 70% of those who died were young children. Pregnant women are also disproportionately affected by malaria, with around 125 million pregnancies at risk every year. Medicines are currently available to treat Plasmodium falciparum malaria, the most prevalent form of the disease in Africa, but these are 3-day treatment courses, and patients often do not complete course. It is widely understood that this lack of compliance carries the risk of parasite resistance developing to the drugs.

In 2008, evidence of resistance to artemisinin combination therapies (ACT), the gold standard antimalarial, was reported at the Thai-Cambodian border region. Today, there is evidence of its spread, as ACTs are taking longer and longer to clear the parasite from patients further afield in South-East Asia. This longer parasite clearance time with ACTs is clear warning that we urgently need new classes of antimalarials. Ideally, a single-dose cure that needs just one administration could ensure that complete treatment is directly observed by the healthcare worker.

The mission of Medicines for Malaria Venture (MMV) is to reduce the burden of malaria by assembling a large pipeline of new, well-tolerated, effective and affordable antimalarials.

MMV is a leading Product Development Partnership (PDP), established in 1999 as a not-for-profit Swiss foundation to counter the perilous absence of new medicines for malaria. Its vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease.

Earlier funding by the Netherlands Ministry of Foreign Affairs (MoFA) has helped MMV build a strong antimalarial portfolio. Over the last 16 years, in collaboration with partners and support from donors, MMV has assembled the largest-ever pipeline of antimalarials, and has brought forward six new medicines, two of which are much-needed paediatric formulations. These new drugs are already saving lives and have helped contribute to the impressive halving of global malaria mortality from 2000 to 2015.
MMV’s overarching priority is to develop child-friendly formulations and new medicines to protect pregnant women, as this group is the hardest hit by malaria. Projects progressing through the pipeline include nine new drugs in clinical development addressing unmet medical needs in malaria, including medicines for this under-served population as well as new treatments for relapsing malaria, and drugs that could support the elimination/eradication agenda. MMV’s portfolio also includes promising compounds in early phases of discovery and preclinical development with the potential to counter resistance, block malaria transmission and cure relapsing malaria, a form of the disease mostly prevalent in Southeast Asia and South America.

Since its foundation MMV has built an impressive network in over 50 countries of more than 375 partners from the public and private sectors, from NGOs and non-profit organizations, and from clinical facilities in disease-endemic countries. With sustained financial support from donors, MMV brings together academic brain, pharmaceutical muscle, and its own wealth of scientific and malaria expertise in a dedicated effort to contribute to the defeat of this disease. This catalytic ability makes MMV a highly cost-effective, productive and successful R&D organization.

Support from the MoFA will enable MMV to strengthen its current portfolio, and help accelerate the provision of key medicines to vulnerable patients who urgently need them.

<table>
<thead>
<tr>
<th>Total budget lead applicant (5 years)</th>
<th>€168,755,233</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contribution by the Netherlands Ministry of Foreign Affairs</td>
<td>€14,942,667</td>
</tr>
</tbody>
</table>

About RVO.nl
Your ambitions include doing business in emerging markets and developing countries. You want to contribute towards a healthy local business and the sustainable economic development of a country. Sometimes you encounter obstacles in relation to financing, a lack of knowledge about market opportunities, or the absence of a business network. You also have to deal with Corporate Social Responsibility and other laws and regulations. For all these questions relating to international enterprise, contact the Netherlands Enterprise Agency. We are your partner in the area of Sustainable, Agricultural, Innovative and International enterprise. For more information, visit www.rvo.nl.

This is a publication of:
Netherlands Enterprise Agency
Prinses Beatrixlaan 2 | 2595 AL The Hague
P.O. Box 10366 | 2501 HJ The Hague
T +31 (0) 88 042 42 42
F +31 (0) 88 602 90 24
www.rvo.nl/pdp
E pdp@rvo.nl

This publication has been commissioned by the Ministry of Foreign Affairs.
© Netherlands Enterprise Agency | February 2016